KR20160079060A - 무정형의 마그네슘-치환된 인산칼슘 조성물 및 그의 용도 - Google Patents

무정형의 마그네슘-치환된 인산칼슘 조성물 및 그의 용도 Download PDF

Info

Publication number
KR20160079060A
KR20160079060A KR1020167014309A KR20167014309A KR20160079060A KR 20160079060 A KR20160079060 A KR 20160079060A KR 1020167014309 A KR1020167014309 A KR 1020167014309A KR 20167014309 A KR20167014309 A KR 20167014309A KR 20160079060 A KR20160079060 A KR 20160079060A
Authority
KR
South Korea
Prior art keywords
calcium phosphate
composition
amorphous magnesium
cargo
substituted calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167014309A
Other languages
English (en)
Korean (ko)
Inventor
조나단 조셉 파월
누노 조르지 로드리게스 파리아
래티티아 펠레
레이첼 휴이트
엠마 토마스-맥케이
Original Assignee
메디칼 리서취 카운실
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디칼 리서취 카운실 filed Critical 메디칼 리서취 카운실
Publication of KR20160079060A publication Critical patent/KR20160079060A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A23L1/29—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
KR1020167014309A 2013-11-05 2014-11-05 무정형의 마그네슘-치환된 인산칼슘 조성물 및 그의 용도 Ceased KR20160079060A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1319548.2 2013-11-05
GBGB1319548.2A GB201319548D0 (en) 2013-11-05 2013-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses
PCT/GB2014/053291 WO2015067939A1 (en) 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses

Publications (1)

Publication Number Publication Date
KR20160079060A true KR20160079060A (ko) 2016-07-05

Family

ID=49767709

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167014309A Ceased KR20160079060A (ko) 2013-11-05 2014-11-05 무정형의 마그네슘-치환된 인산칼슘 조성물 및 그의 용도

Country Status (16)

Country Link
US (1) US10596122B2 (enExample)
EP (1) EP3065715B1 (enExample)
JP (2) JP2016537408A (enExample)
KR (1) KR20160079060A (enExample)
CN (1) CN105722504A (enExample)
AU (1) AU2014345334B2 (enExample)
BR (1) BR112016009809A2 (enExample)
CA (1) CA2929123A1 (enExample)
EA (1) EA201690659A1 (enExample)
ES (1) ES2761559T3 (enExample)
GB (1) GB201319548D0 (enExample)
IL (1) IL245380B (enExample)
MX (1) MX367473B (enExample)
SG (2) SG10201803562YA (enExample)
WO (1) WO2015067939A1 (enExample)
ZA (1) ZA201602906B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180012484A (ko) * 2016-07-27 2018-02-06 삼일제약주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
WO2026029321A1 (ko) * 2024-08-02 2026-02-05 한국과학기술연구원 레이저를 이용한 아파타이트 분말 연속 합성 장치 및 방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
FR3021045B1 (fr) * 2014-05-16 2020-02-21 Solvay Sa Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation
EP3538659A4 (en) * 2016-11-09 2020-07-15 Engene, Inc. INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1
CN110573455A (zh) * 2017-04-27 2019-12-13 武礼伟仁株式会社 羟基磷灰石、化妆品和食品及其生产方法
WO2021003601A1 (zh) * 2019-07-05 2021-01-14 广州中大医疗器械有限公司 一种新型可载药微球及其制备方法
WO2021086252A1 (en) 2019-10-30 2021-05-06 Psilox Ab Stabilized amorphous calcium magnesium phosphate particle compositions
CN116768175B (zh) * 2023-07-01 2025-12-19 常州市第二人民医院 高稳定性生物活性无定形磷酸钙镁的制备方法及应用
CN118929595A (zh) * 2024-08-30 2024-11-12 昆明理工大学 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
EP1872798B1 (en) 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
EP2106217B1 (en) 2006-12-12 2019-03-13 Firmenich S.A. Active ingredient delivery system with an amorphous metal salt as carrier
US20120128767A1 (en) * 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180012484A (ko) * 2016-07-27 2018-02-06 삼일제약주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
WO2026029321A1 (ko) * 2024-08-02 2026-02-05 한국과학기술연구원 레이저를 이용한 아파타이트 분말 연속 합성 장치 및 방법

Also Published As

Publication number Publication date
US10596122B2 (en) 2020-03-24
MX2016005415A (es) 2017-03-01
AU2014345334B2 (en) 2019-10-31
ZA201602906B (en) 2019-09-25
EA201690659A1 (ru) 2016-10-31
MX367473B (es) 2019-08-23
IL245380A0 (en) 2016-06-30
WO2015067939A1 (en) 2015-05-14
ES2761559T3 (es) 2020-05-20
US20160235683A1 (en) 2016-08-18
GB201319548D0 (en) 2013-12-18
IL245380B (en) 2019-02-28
EP3065715B1 (en) 2019-10-02
AU2014345334A1 (en) 2016-05-19
JP2016537408A (ja) 2016-12-01
BR112016009809A2 (pt) 2017-12-05
EP3065715A1 (en) 2016-09-14
JP2020073467A (ja) 2020-05-14
CA2929123A1 (en) 2015-05-14
SG11201603261PA (en) 2016-05-30
SG10201803562YA (en) 2018-06-28
CN105722504A (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
EP3065715B1 (en) Amorphous magnesium-substituted calcium phosphate compositions and their uses
AU2020267191B2 (en) Polymeric bile acid nanocompositions targeting the pancreas and colon
CN114470223B (zh) 清除促炎因子和抑制t细胞活化的细胞膜包被纳米诱饵及其制备方法与应用
WO2010009735A2 (en) Combinatorial analysis and repair
Cheng et al. Anti-cancer efficacy of biotinylated chitosan nanoparticles in liver cancer
KR20200109352A (ko) 랑게린+ 세포 표적화
JP2016537408A5 (enExample)
WO2018113684A1 (zh) 富勒烯结构在制备治疗白血病的药物中的应用
WO2014034669A1 (ja) 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法
Zheng et al. Inulin acetate as a novel recombinant subunit vaccine carrier for immunization of tilapia against tilapia lake virus
CN114376974B (zh) 一种微环境酶靶向联合抗体Fab细胞靶向载体及其制备方法和应用
CN117940137A (zh) 人工酶-细菌系统及其用途
CN114288249A (zh) 一种调控病灶微环境Treg/Th17细胞比例的纳米免疫调控药物及其制备方法和应用
JPH10147534A (ja) 腫瘍新生血管阻害物質及び医薬組成物
Nayak et al. Chitosan micro and nanoparticles for delivery of drugs and therapeutic proteins
Loghmani et al. Targeted Nanoparticle Therapy with Betaine-Conjugated Gold Nanoparticles Reduces Inflammation and Makes Immunomodulation in Heatstroke in Mice
Zhang et al. Hyaluronate-based Self-stabilized Nanoparticles for Reverting Immunosuppression and Immunochemotherapy in Osteosarcoma Treatment
WO2025147671A1 (en) Immune cell-specific protein degraders and methods of use thereof for immunotherapy
Mathew Investigating the biophysical, biochemical, and biological activity of anti-cancer zinc oxide nanoparticle and its physiometacomposite (PMC) nanoparticles
CN114306241A (zh) 一种微环境t细胞功能调控的纳米递送系统及其制备方法和应用
CN121668411A (zh) 一种负载msa-2和b7-h3抗体的植入式支架及其在骨转移免疫治疗中的应用
CN114404367A (zh) 一种通过对病变细胞靶向分布的纳米载体及其制备方法和应用
Italiani et al. Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20190211

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191105

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20191105

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200205

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200608

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200205

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I